Upside Potential From Possible Transaction At PAREXEL International

On May 8, 2017 The Wall Street Journal reported PAREXEL International Corporation ( PRXL) hired bankers to explore a possible sale. The following is an update to my previous valuation of the company and an analysis of how the transaction may offer an opportunity for investors to profit from the possible transaction being contemplated by PRXL management.

For those not familiar with the company and/or the market sector which the company operates in: "PAREXEL International Corporation", "is a leading bio-pharmaceutical outsourcing services company, providing a broad range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries." "Primary objective of the company is to provide solutions for managing the bio-pharmaceutical product lifecycle with the goal of reducing the time, risk, and cost associated with the development and commercialization of new therapies." Source: PRXL 10-K

READ FULL ARTICLE HERE